Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navtemadlin - Kartos Therapeutics

Drug Profile

Navtemadlin - Kartos Therapeutics

Alternative Names: AMG 232; KRT-232

Latest Information Update: 14 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; GSK; Kartos Therapeutics; National Cancer Institute (USA); Telios Pharmaceuticals; Vanderbilt University Medical Center
  • Class Acetic acids; Antineoplastics; Chlorobenzenes; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Endometrial cancer; Myelofibrosis
  • Phase II Polycythaemia vera; Small cell lung cancer
  • Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Malignant melanoma; Merkel cell carcinoma
  • No development reported Adenoid cystic carcinoma; Glioblastoma; Multiple myeloma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 22 Mar 2024 Kartos Therapeutics withdraws prior to enrollment a phase I/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) (PO) due to sponsor's decision (NCT05705466)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical data in Acute Myeloid Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Newly diagnosed) in USA (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top